Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Medcan FX02
- Development stage
- Phase 3
- Lead developer
- Medcan Australia
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Sublingual
01
Overview
Medcan FX02 is a medicinal cannabis oil developed by Medcan Australia. It is a balanced formulation containing 5 mg/mL of tetrahydrocannabinol (THC) and 8 mg/mL of cannabidiol (CBD) in a pharmaceutical-grade carrier oil. In Australia, Medcan FX02 is available as an unapproved therapeutic good through the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS Category A/B) and the Authorised Prescriber Scheme. It is primarily prescribed for the management of conditions such as chronic pain, anxiety, and sleep disorders (insomnia), leveraging the synergistic effects of THC and CBD on the endocannabinoid system, specifically targeting cannabinoid receptors CB1 and CB2.
- Brand names
- Medcan FX02
- Other names
- Medcan FX02 Cannabis OilMedcan FX02 Oil
02
Targets
CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on Medcan FX02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Medcan FX02.